Related Experiment Video
Updated: Jun 9, 2025
Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
Published on: August 21, 2013
PARP inhibitors in prostate cancer: clinical applications
Hamidreza Saeidi1, Mohsen Sarafbidabad2
1Department of Biomedical Science, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Malaysia.
Abstract:
Despite recent advancements in the treatment of metastatic castrate-resistant prostate cancer (mCRPC), this disease remains lethal. A novel family of targeted pharmaceuticals known as poly-ADP-ribose polymerase (PARP) inhibitors has been developed to treat mCRPC patients with homologous recombination repair (HRR) gene alterations. The FDA recently approved olaparib and rucaparib for treating mCRPC patients with HRR gene alterations. Ongoing trials are investigating combination therapies involving PARP inhibitors combined with radiation, chemotherapy, immunotherapy, and androgen receptor signaling inhibitors (ARSIs) to improve the effectiveness of PARP inhibitors and broaden the range of patients who can benefit from the treatment. This review provides an overview of the development of PARP inhibitors in prostate cancer and analyzes the mechanisms underlying their resistance.
Insights
Poly(ADP-ribose) polymerase (PARP) inhibitors offer new hope for metastatic castrate-resistant prostate cancer (mCRPC) patients with specific gene alterations. Research is exploring combination therapies to enhance treatment effectiveness and overcome resistance mechanisms.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Metastatic castrate-resistant prostate cancer (mCRPC) remains a significant cause of cancer-related death.
- Homologous recombination repair (HRR) gene alterations are key targets for novel therapies.
- Poly(ADP-ribose) polymerase (PARP) inhibitors represent a promising class of targeted drugs.
Purpose of the Study:
- To review the development and application of PARP inhibitors in prostate cancer treatment.
- To analyze the mechanisms of resistance to PARP inhibitors.
- To explore ongoing research into combination therapies.
Main Methods:
- Literature review of clinical trials and preclinical studies.
- Analysis of genetic alterations in prostate cancer.
- Examination of drug resistance pathways.
Main Results:
- Olaparib and rucaparib are FDA-approved for mCRPC patients with HRR alterations.
- Combination therapies with PARP inhibitors are under investigation.
- Understanding resistance mechanisms is crucial for improving outcomes.
Conclusions:
- PARP inhibitors have emerged as a vital treatment modality for a subset of mCRPC patients.
- Further research into combination strategies and resistance mechanisms is essential.
- Optimizing PARP inhibitor therapy holds potential for improving survival in advanced prostate cancer.
More Related Videos
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
02:34Inhibition of Cdk Activity
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...